Research and Markets Adds Report: EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022
Feb 27, 2013 (Close-Up Media via COMTEX) --
Research and Markets has announced the addition of GlobalData's new report "EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022" to its offerings.
In a release, Research and Markets noted that report highlights include:
Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system, destroying or impairing their function. The most advanced stage of HIV infection is acquired immunodeficiency syndrome (AIDS). Approximately 34 million people are living with HIV around the world, with an estimated 2.7 million new infections each year, and the size of HIV/AIDS incident and prevalent populations vary widely between countries (UNAIDS, 2011). GlobalData epidemiologists forecast incident cases of HIV will increase 9.7 percent over the next decade in the 10 markets, from 276,590 incident cases in 2012 to 303,365 incident cases in 2022.
In the 10 markets, GlobalData epidemiologists calculated that approximately 5.39 million prevalent cases of HIV occurred in 2012. The number of prevalent cases of HIV is expected to grow almost 15 percent over the next decade to 6.1 million by 2022. Although all countries covered in this report have introduced a number of preventive programs and government-led interventions among HIV high-risk populations, the burden of HIV is expected to continue. Sustained levels of high-risk behaviors along with population growth make it challenging to control the future burden of HIV.
Furthermore, the prognosis of people with HIV has improved dramatically over time with the introduction of new and improved treatments. Given this scenario, GlobalData epidemiologists expect that although the burden of HIV incidence may be controlled in the seven major markets and Brazil, the likely increase in incidence in India and China is expected to continue for the next decade. Additionally, with the introduction of anti-retroviral therapy among India and China, the number of prevalent cases is expected to increase in these markets.
((Comments on this story may be sent to email@example.com))
[ InfoTech Spotlight's Homepage ]